Mohamed Zakaria Khalil
Objectives: Clinical application of #ACC17 highlights towards State-of-Art cardiology practice is the motive for this article. The novel new therapeutic pathway thru inhibition of PCSK9 is the current breakthrough in lowering LDLCholesterol (LDL-C) to desired levels, however, robust clinical cardiovascular outcomes evidence is still at large.
Methods: Extraction and analysis of the documented published medical literature on LDL-C in view of novel therapeutic PCSK9. Inhibitors capability in lowering LDL cholesterol that has been remarkably shown by FOURIER trial investigators to be safe and effective.
Results: LDL-C is reduced to very low levels of 20-30 mg/dL in patients with high risk for vascular thrombosis. Two percent (~2%) absolute risk reduction is observed in clinical outcomes. In patients treated to very low levels of LDL-C, 2.9% developed acute coronary syndrome (ACS) compared to 4% in the placebo arm.
Conclusion: PCSK9 inhibition is effective and safe in lowering LDL-C to very low levels in high risk patients with modest reduction in clinical outcomes despite control of other risk factors.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 